Compare Royal Caribbean Cruises Ltd (RCL) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Royal Caribbean Cruises Ltd vs Zoetis Inc — how do they compare? Royal Caribbean Cruises Ltd trades at $282.26 (market cap $75.26B), while Zoetis Inc trades at $74.77 (market cap $30.20B). The key difference: Royal Caribbean Cruises Ltd is far larger — about 2.5× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals — on Pluang, investors hold Royal Caribbean Cruises Ltd for 85 Days and Zoetis Inc for 70 Days on average.
| RCL | ZTS | |
|---|---|---|
Market Cap | $75.26B | $30.20B |
Volume | 1,958,628 | 6,175,327 |
Sector | Consumer Cyclical | Health |
52-Week High | $348.03 | $147.53 |
52-Week Low | $230.30 | $69.09 |
Typical Hold Time | 85 Days | 70 Days |
Enterprise Value | $97.91B | $37.76B |
Dividend Yield | 2.13% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Royal Caribbean (RCL) trades at $281.39, showing modest daily weakness but maintaining strong bullish momentum with analyst consensus pointing to significant upside. The company demonstrates robust fundamentals with revenue growth from $8.8B in 2022 to $17.9B in 2025, net income margin expanding to 23.54%, and positive cash flow generation. Recent developments include a $3B investment in Sandals Resorts and strong Q2 2026 earnings beat, while technical indicators show the stock trading near key resistance levels with overall bullish signals.
RCL presents compelling investment potential with 23% upside to consensus price target of $346.67, supported by strong earnings momentum and expanding profitability. However, risks include elevated debt levels, execution challenges from the Sandals acquisition, and sensitivity to fuel price volatility. The stock's current valuation at 17.38x P/E appears reasonable given the company's growth trajectory and industry-leading margins.
Zoetis (ZTS) trades at $73.08, up 2.14% today, with a bullish technical signal but mixed earnings history including a recent Q1 2026 miss. The stock shows strong profitability with a 27.69% net income margin and 64.91% ROE, while valuation metrics like a P/E of 11.92 appear reasonable. Recent news highlights competitive pressures in the U.S. pet care market, though international segments remain resilient.
The outlook is cautiously optimistic; ZTS faces near-term headwinds from weak U.S. demand and competition, but its industry-leading margins and dominant market position support long-term growth. Risks include pricing erosion and guidance cuts, yet the consensus price target of $87.33 suggests upside potential for patient investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
